Abstract
Cancer stem cells (CSC) have been suggested as a mechanism of resistance and relapse in BC. TN and HER2+ BC have been associated with a more immunogenic tumor microenvironment, with higher presence of tumor-infiltrating lymphocytes (TILs) and activation of pathways as PD-L1. ALDH1 is a CSC marker that appears to be predictive of clinical outcomes. The study aims to analyze ALDH1 and PD-L1 expression, and the presence of TILs in TN and HER2+ BC tumors, and its association with clinical-pathological characteristics and clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
